Multiplex Assays Market by Product & Service (Consumable, Instrument), Type (Protein, Nucleic Acid), Technology (Flow Cytometry), Application [R&D, Diagnostics (Infectious Disease, Cancer)], End User (Hospital, Research Institute)-Global Forecast to 2031
The market for multiplex assays is projected to be valued at approximately USD 7.15 billion in 2026 and is expected to reach USD 10.65 billion by 2031, reflecting a 8.3% growth rate. This steady growth is driven by medical institutions' growing focus on early diagnosis, accurate biomarkers, and improved patient outcomes. Factors such as the increasing complexity of diseases, the rise of personalized medicine, and the need for efficient, high-throughput testing methods are driving the growing global demand for multiplex assays.
“By product & service, the consumables segment is predicted to showcase the highest CAGR during the forecast period.”
The growth in this segment is primarily driven by the consistent need for multiplex assay kits, reagents, beads, primers, probes, and controls, all of which are essential for conducting analyses. The rising incidence of infectious diseases, cancers, and autoimmune conditions is expected to increase testing demand across various healthcare settings. This will boost demand for the segment in hospitals, diagnostic labs, and research facilities. Additionally, the expanding use of multiplex testing protocols and the development of new assays will further contribute to this growth.
“By technology, the Flow cytometry segment is projected to hold the largest share of the multiplex assay market in 2026.”
This market segment is dominant due to the widespread adoption of technology in hospitals and reference laboratories, enabling high-throughput and multiparametric testing with improved sensitivity, accuracy, and reproducibility in biomarker and cell analysis. Flow cytometry is among the most widely used instruments in immunology, oncology, and translational research, owing to its ability to rapidly analyze multiple markers in a single test. The demand for flow cytometers is primarily driven by the increasing number of diagnostic tests, scientific studies, and the need for disease profiling and therapy monitoring.
“The Asia Pacific is expected to register the fastest growth rate in the multiplex assay market.”
This region is experiencing rapid growth due to several factors, including the expansion of healthcare facilities and increased healthcare spending. The modernization of hospitals, laboratories, and diagnostic centers is also contributing to this growth. Additionally, the rising incidence of infectious diseases, cancer, and chronic conditions is driving the demand for advanced diagnostic tests. Furthermore, increased investments in biotechnology research, the expansion of pharmaceutical production facilities, and a growing number of diagnostic centers are fueling the growth of multiplex assays in the Asia Pacific region. Key countries contributing to this market growth include China, India, Japan, and South Korea, among others.
The break-up of the profile of primary participants in the multiplex assay market:
Research Coverage:
This research report categorizes the multiplex assay market by product & service (consumables, instruments, software & services), type (protein multiplex assays, nucleic acid multiplex assays, cell-based multiplex assays), technology (flow cytometry, fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing (NGS), other technologies), application (research & development, clinical diagnostics), end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, contract research organizations, other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the multiplex assay market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the multiplex assay market. This report covers the competitive analysis of upcoming startups in the multiplex assay market ecosystem.
Reasons to buy this report:
The report will help market leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall multiplex assay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
“By product & service, the consumables segment is predicted to showcase the highest CAGR during the forecast period.”
The growth in this segment is primarily driven by the consistent need for multiplex assay kits, reagents, beads, primers, probes, and controls, all of which are essential for conducting analyses. The rising incidence of infectious diseases, cancers, and autoimmune conditions is expected to increase testing demand across various healthcare settings. This will boost demand for the segment in hospitals, diagnostic labs, and research facilities. Additionally, the expanding use of multiplex testing protocols and the development of new assays will further contribute to this growth.
“By technology, the Flow cytometry segment is projected to hold the largest share of the multiplex assay market in 2026.”
This market segment is dominant due to the widespread adoption of technology in hospitals and reference laboratories, enabling high-throughput and multiparametric testing with improved sensitivity, accuracy, and reproducibility in biomarker and cell analysis. Flow cytometry is among the most widely used instruments in immunology, oncology, and translational research, owing to its ability to rapidly analyze multiple markers in a single test. The demand for flow cytometers is primarily driven by the increasing number of diagnostic tests, scientific studies, and the need for disease profiling and therapy monitoring.
“The Asia Pacific is expected to register the fastest growth rate in the multiplex assay market.”
This region is experiencing rapid growth due to several factors, including the expansion of healthcare facilities and increased healthcare spending. The modernization of hospitals, laboratories, and diagnostic centers is also contributing to this growth. Additionally, the rising incidence of infectious diseases, cancer, and chronic conditions is driving the demand for advanced diagnostic tests. Furthermore, increased investments in biotechnology research, the expansion of pharmaceutical production facilities, and a growing number of diagnostic centers are fueling the growth of multiplex assays in the Asia Pacific region. Key countries contributing to this market growth include China, India, Japan, and South Korea, among others.
The break-up of the profile of primary participants in the multiplex assay market:
- By Company Type: Tier 1 (35%), Tier 2 (40%), and Tier 3 (15%)
- By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
- By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)
Research Coverage:
This research report categorizes the multiplex assay market by product & service (consumables, instruments, software & services), type (protein multiplex assays, nucleic acid multiplex assays, cell-based multiplex assays), technology (flow cytometry, fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing (NGS), other technologies), application (research & development, clinical diagnostics), end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, contract research organizations, other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the multiplex assay market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the multiplex assay market. This report covers the competitive analysis of upcoming startups in the multiplex assay market ecosystem.
Reasons to buy this report:
The report will help market leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall multiplex assay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (rising incidence of chronic and infectious diseases, advantages over singleplex and traditional assays, increasing use of multiplex assays in companion diagnostics, growing focus on early disease detection, rising incidence of chronic and infectious diseases), restraints (cost constraints associated with multiplex assay instrumentation, regulatory challenges and stringent quality standards), opportunities (growing validation of biomarkers in molecular and protein-based diagnostics, advancements in biomarker validation in molecular and protein diagnostics, expansion in emerging markets), and challenges (shortage of skilled professionals, complex data analysis and interpretation).
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the multiplex assay market.
- Market Development: Comprehensive information about lucrative markets; the report analyses the multiplex assay market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiplex assay market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN MULTIPLEX ASSAY MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MULTIPLEX ASSAY MARKET
3.2 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
3.3 MULTIPLEX ASSAY MARKET, BY TYPE, 2026 VS. 2031
3.4 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.5 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2026 VS. 2031
3.6 MULTIPLEX ASSAY MARKET, BY END USER, 2026 VS. 2031
3.7 MULTIPLEX ASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising incidence of chronic and infectious diseases
4.2.1.2 Advantages over singleplex and traditional assays
4.2.1.3 Increasing use of multiplex assays in companion diagnostics
4.2.1.4 Growing focus on early disease detection
4.2.1.5 Expansion of biomarker-driven research
4.2.2 RESTRAINTS
4.2.2.1 Cost constraints associated with multiplex assay instrumentation
4.2.2.2 Regulatory challenges and stringent quality standards
4.2.3 OPPORTUNITIES
4.2.3.1 Growing validation of biomarkers in molecular and protein-based diagnostics
4.2.3.2 Expansion in emerging markets
4.2.4 CHALLENGES
4.2.4.1 Shortage of skilled professionals
4.2.4.2 Complex data analysis and interpretation
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN MULTIPLEX ASSAY MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 MULTIPLEX ASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 3822)
5.7.2 EXPORT SCENARIO (HS CODE 3822)
5.8 KEY CONFERENCES AND EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT AND FUNDING SCENARIO
5.11 IMPACT OF 2025 US TARIFF ON MULTIPLEX ASSAY MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGION
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 MULTIPLEX REAL-TIME PCR
6.1.2 FLOW CYTOMETRY
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 BIOINFORMATICS
6.2.2 MICROFLUIDICS
6.3 ADJACENT TECHNOLOGIES
6.3.1 NEXT-GENERATION SEQUENCING
6.3.2 DIGITAL PCR
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 LIST OF KEY PATENTS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON MULTIPLEX ASSAY MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES AND MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAYS
7.2.1.1 Eco-friendly initiatives
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE
9.1 INTRODUCTION
9.2 CONSUMABLES
9.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
9.3 INSTRUMENTS
9.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
9.4 SOFTWARE & SERVICES
9.4.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE
10 MULTIPLEX ASSAY MARKET, BY TYPE
10.1 INTRODUCTION
10.2 PROTEIN MULTIPLEX ASSAYS
10.2.1 BEAD-BASED PROTEIN ASSAYS
10.2.1.1 Best suited to study protein-protein interactions
10.2.2 PLANAR PROTEIN ASSAYS
10.2.2.1 Pivotal role in drug discovery to support uptake
10.2.3 OTHER PROTEIN ASSAYS
10.3 NUCLEIC ACID MULTIPLEX ASSAYS
10.3.1 BEAD-BASED NUCLEIC ACID ASSAYS
10.3.1.1 Increasing infectious diseases and genetic screening tests to drive market
10.3.2 PLANAR NUCLEIC ACID ASSAYS
10.3.2.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis
10.3.3 OTHER NUCLEIC ACID ASSAYS
10.4 CELL-BASED MULTIPLEX ASSAYS
10.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET
11 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY
11.1 INTRODUCTION
11.2 FLOW CYTOMETRY
11.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO DRIVE SEGMENT
11.3 FLUORESCENCE DETECTION
11.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL SEGMENT GROWTH
11.4 MULTIPLEX REAL-TIME PCR
11.4.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
11.5 LUMINESCENCE
11.5.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
11.6 NEXT-GENERATION SEQUENCING (NGS)
11.6.1 RISING ADOPTION OF CUSTOMIZED AND APPLICATION-SPECIFIC NGS MULTIPLEX PANELS TO DRIVE MARKET
11.7 OTHER TECHNOLOGIES
12 MULTIPLEX ASSAY MARKET, BY APPLICATION
12.1 INTRODUCTION
12.2 RESEARCH & DEVELOPMENT
12.2.1 DRUG DISCOVERY & DEVELOPMENT
12.2.1.1 Multiplex assays massively employed in preclinical and clinical phases
12.2.2 BIOMARKER DISCOVERY & VALIDATION
12.2.2.1 Advancing biomarker discovery through global collaborative research networks
12.3 CLINICAL DIAGNOSTICS
12.3.1 INFECTIOUS DISEASES
12.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays
12.3.2 CANCER
12.3.2.1 Rising burden of cancer to drive market
12.3.3 CARDIOVASCULAR DISEASES
12.3.3.1 High burden of cardiovascular diseases to support market growth
12.3.4 AUTOIMMUNE DISEASES
12.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis
12.3.5 NERVOUS SYSTEM DISORDERS
12.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment
12.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
12.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers help in timely diagnosis
12.3.7 OTHER DISEASES
13 MULTIPLEX ASSAY MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE MARKET
13.3 HOSPITALS & DIAGNOSTIC LABORATORIES
13.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
13.4 ACADEMIC & RESEARCH INSTITUTES
13.4.1 RISING GOVERNMENT FUNDING TO ACCELERATE MULTIPLEX ADOPTION IN ACADEMIC RESEARCH
13.5 CONTRACT RESEARCH ORGANIZATIONS
13.5.1 RISING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES TO ACCELERATE MULTIPLEX ASSAY ADOPTION AMONG CROS
13.6 OTHER END USERS
14 MULTIPLEX ASSAY MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market
14.2.2 CANADA
14.2.2.1 Favorable government initiatives to fuel market
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Strong healthcare infrastructure to drive market
14.3.2 UK
14.3.2.1 Expansion of diagnostic infrastructure to drive market
14.3.3 FRANCE
14.3.3.1 Strong R&D investments and growing disease burden to drive market
14.3.4 ITALY
14.3.4.1 Growing adoption of advanced diagnostics to drive market
14.3.5 SPAIN
14.3.5.1 Rising disease burden to drive market
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Strong healthcare investments to drive market
14.4.2 JAPAN
14.4.2.1 Universal healthcare reimbursement policy to foster market growth
14.4.3 INDIA
14.4.3.1 Increased private and public investments to bolster growth
14.4.4 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 Rising disease burden and expanding research ecosystem to drive market
14.5.2 MEXICO
14.5.2.1 Rising chronic disease burden to drive market
14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 GROWING HEALTHCARE INVESTMENTS AND RISING DEMAND FOR MULTIPLEX TESTING TO DRIVE MARKET
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MULTIPLEX ASSAY MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.4.1 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Product & service footprint
15.5.5.4 Application footprint
15.5.5.5 End user footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SMEs (1/2)
15.6.5.3 Competitive benchmarking of key startups/SMEs (2/2)
15.7 COMPANY VALUATION AND FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 ILLUMINA, INC.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & approvals
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 BIO-RAD LABORATORIES, INC.
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 THERMO FISHER SCIENTIFIC INC.
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches & approvals
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 DIASORIN S.P.A.
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product launches & approvals
16.1.4.3.2 Deals
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 BIOM?RIEUX
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches & approvals
16.1.5.3.2 Deals
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses & competitive threats
16.1.6 BECTON, DICKINSON AND COMPANY
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches & approvals
16.1.6.3.2 Deals
16.1.7 QIAGEN N.V.
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches & approvals
16.1.7.3.2 Deals
16.1.8 MERCK KGAA
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.8.3.2 Expansions
16.1.9 AGILENT TECHNOLOGIES, INC.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches & approvals
16.1.9.3.2 Deals
16.1.10 DANAHER CORPORATION
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches & approvals
16.1.10.3.2 Deals
16.1.11 REVVITY, INC.
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches & approvals
16.1.11.3.2 Deals
16.1.12 F. HOFFMANN-LA ROCHE LTD
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches & approvals
16.1.12.3.2 Deals
16.1.13 QUANTERIX CORPORATION
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Product launches & approvals
16.1.13.3.2 Deals
16.2 OTHER PLAYERS
16.2.1 BIO-TECHNE CORPORATION
16.2.2 SEEGENE INC.
16.2.3 MESO SCALE DIAGNOSTICS LLC
16.2.4 RANDOX LABORATORIES LTD.
16.2.5 STANDARD BIOTOOLS INC.
16.2.6 HOLOGIC, INC.
16.2.7 ABBOTT LABORATORIES
16.2.8 SIEMENS HEALTHINEERS AG
16.2.9 ENZO BIOCHEM INC.
16.2.10 SHIMADZU CORPORATION
16.2.11 PROMEGA CORPORATION
16.2.12 BOSTER BIOLOGICAL TECHNOLOGY
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY RESEARCH
17.1.1.1 Key data from secondary sources
17.1.2 PRIMARY DATA
17.1.2.1 Primary sources
17.1.2.2 Key data from primary sources
17.1.2.3 Key industry insights
17.2 MARKET SIZE ESTIMATION
17.2.1 BOTTOM-UP APPROACH
17.2.1.1 Approach 1: Company revenue estimation approach
17.2.1.2 Approach 2: Presentations of companies and primary interviews
17.2.1.3 Growth forecast
17.2.2 TOP-DOWN APPROACH
17.3 MARKET BREAKDOWN AND DATA TRIANGULATION
17.4 MARKET SHARE ANALYSIS
17.5 RESEARCH ASSUMPTIONS
17.5.1 PARAMETRIC ASSUMPTIONS
17.5.2 GROWTH RATE ASSUMPTIONS
17.6 RESEARCH LIMITATIONS
17.7 RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN MULTIPLEX ASSAY MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MULTIPLEX ASSAY MARKET
3.2 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
3.3 MULTIPLEX ASSAY MARKET, BY TYPE, 2026 VS. 2031
3.4 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.5 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2026 VS. 2031
3.6 MULTIPLEX ASSAY MARKET, BY END USER, 2026 VS. 2031
3.7 MULTIPLEX ASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising incidence of chronic and infectious diseases
4.2.1.2 Advantages over singleplex and traditional assays
4.2.1.3 Increasing use of multiplex assays in companion diagnostics
4.2.1.4 Growing focus on early disease detection
4.2.1.5 Expansion of biomarker-driven research
4.2.2 RESTRAINTS
4.2.2.1 Cost constraints associated with multiplex assay instrumentation
4.2.2.2 Regulatory challenges and stringent quality standards
4.2.3 OPPORTUNITIES
4.2.3.1 Growing validation of biomarkers in molecular and protein-based diagnostics
4.2.3.2 Expansion in emerging markets
4.2.4 CHALLENGES
4.2.4.1 Shortage of skilled professionals
4.2.4.2 Complex data analysis and interpretation
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN MULTIPLEX ASSAY MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 MULTIPLEX ASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 3822)
5.7.2 EXPORT SCENARIO (HS CODE 3822)
5.8 KEY CONFERENCES AND EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT AND FUNDING SCENARIO
5.11 IMPACT OF 2025 US TARIFF ON MULTIPLEX ASSAY MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGION
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 MULTIPLEX REAL-TIME PCR
6.1.2 FLOW CYTOMETRY
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 BIOINFORMATICS
6.2.2 MICROFLUIDICS
6.3 ADJACENT TECHNOLOGIES
6.3.1 NEXT-GENERATION SEQUENCING
6.3.2 DIGITAL PCR
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 LIST OF KEY PATENTS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON MULTIPLEX ASSAY MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES AND MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAYS
7.2.1.1 Eco-friendly initiatives
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE
9.1 INTRODUCTION
9.2 CONSUMABLES
9.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
9.3 INSTRUMENTS
9.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
9.4 SOFTWARE & SERVICES
9.4.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE
10 MULTIPLEX ASSAY MARKET, BY TYPE
10.1 INTRODUCTION
10.2 PROTEIN MULTIPLEX ASSAYS
10.2.1 BEAD-BASED PROTEIN ASSAYS
10.2.1.1 Best suited to study protein-protein interactions
10.2.2 PLANAR PROTEIN ASSAYS
10.2.2.1 Pivotal role in drug discovery to support uptake
10.2.3 OTHER PROTEIN ASSAYS
10.3 NUCLEIC ACID MULTIPLEX ASSAYS
10.3.1 BEAD-BASED NUCLEIC ACID ASSAYS
10.3.1.1 Increasing infectious diseases and genetic screening tests to drive market
10.3.2 PLANAR NUCLEIC ACID ASSAYS
10.3.2.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis
10.3.3 OTHER NUCLEIC ACID ASSAYS
10.4 CELL-BASED MULTIPLEX ASSAYS
10.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET
11 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY
11.1 INTRODUCTION
11.2 FLOW CYTOMETRY
11.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO DRIVE SEGMENT
11.3 FLUORESCENCE DETECTION
11.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL SEGMENT GROWTH
11.4 MULTIPLEX REAL-TIME PCR
11.4.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
11.5 LUMINESCENCE
11.5.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
11.6 NEXT-GENERATION SEQUENCING (NGS)
11.6.1 RISING ADOPTION OF CUSTOMIZED AND APPLICATION-SPECIFIC NGS MULTIPLEX PANELS TO DRIVE MARKET
11.7 OTHER TECHNOLOGIES
12 MULTIPLEX ASSAY MARKET, BY APPLICATION
12.1 INTRODUCTION
12.2 RESEARCH & DEVELOPMENT
12.2.1 DRUG DISCOVERY & DEVELOPMENT
12.2.1.1 Multiplex assays massively employed in preclinical and clinical phases
12.2.2 BIOMARKER DISCOVERY & VALIDATION
12.2.2.1 Advancing biomarker discovery through global collaborative research networks
12.3 CLINICAL DIAGNOSTICS
12.3.1 INFECTIOUS DISEASES
12.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays
12.3.2 CANCER
12.3.2.1 Rising burden of cancer to drive market
12.3.3 CARDIOVASCULAR DISEASES
12.3.3.1 High burden of cardiovascular diseases to support market growth
12.3.4 AUTOIMMUNE DISEASES
12.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis
12.3.5 NERVOUS SYSTEM DISORDERS
12.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment
12.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
12.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers help in timely diagnosis
12.3.7 OTHER DISEASES
13 MULTIPLEX ASSAY MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE MARKET
13.3 HOSPITALS & DIAGNOSTIC LABORATORIES
13.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
13.4 ACADEMIC & RESEARCH INSTITUTES
13.4.1 RISING GOVERNMENT FUNDING TO ACCELERATE MULTIPLEX ADOPTION IN ACADEMIC RESEARCH
13.5 CONTRACT RESEARCH ORGANIZATIONS
13.5.1 RISING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES TO ACCELERATE MULTIPLEX ASSAY ADOPTION AMONG CROS
13.6 OTHER END USERS
14 MULTIPLEX ASSAY MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market
14.2.2 CANADA
14.2.2.1 Favorable government initiatives to fuel market
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Strong healthcare infrastructure to drive market
14.3.2 UK
14.3.2.1 Expansion of diagnostic infrastructure to drive market
14.3.3 FRANCE
14.3.3.1 Strong R&D investments and growing disease burden to drive market
14.3.4 ITALY
14.3.4.1 Growing adoption of advanced diagnostics to drive market
14.3.5 SPAIN
14.3.5.1 Rising disease burden to drive market
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Strong healthcare investments to drive market
14.4.2 JAPAN
14.4.2.1 Universal healthcare reimbursement policy to foster market growth
14.4.3 INDIA
14.4.3.1 Increased private and public investments to bolster growth
14.4.4 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 Rising disease burden and expanding research ecosystem to drive market
14.5.2 MEXICO
14.5.2.1 Rising chronic disease burden to drive market
14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 GROWING HEALTHCARE INVESTMENTS AND RISING DEMAND FOR MULTIPLEX TESTING TO DRIVE MARKET
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MULTIPLEX ASSAY MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.4.1 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Product & service footprint
15.5.5.4 Application footprint
15.5.5.5 End user footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SMEs (1/2)
15.6.5.3 Competitive benchmarking of key startups/SMEs (2/2)
15.7 COMPANY VALUATION AND FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 ILLUMINA, INC.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & approvals
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 BIO-RAD LABORATORIES, INC.
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 THERMO FISHER SCIENTIFIC INC.
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches & approvals
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 DIASORIN S.P.A.
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product launches & approvals
16.1.4.3.2 Deals
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 BIOM?RIEUX
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches & approvals
16.1.5.3.2 Deals
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses & competitive threats
16.1.6 BECTON, DICKINSON AND COMPANY
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches & approvals
16.1.6.3.2 Deals
16.1.7 QIAGEN N.V.
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches & approvals
16.1.7.3.2 Deals
16.1.8 MERCK KGAA
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.8.3.2 Expansions
16.1.9 AGILENT TECHNOLOGIES, INC.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches & approvals
16.1.9.3.2 Deals
16.1.10 DANAHER CORPORATION
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches & approvals
16.1.10.3.2 Deals
16.1.11 REVVITY, INC.
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches & approvals
16.1.11.3.2 Deals
16.1.12 F. HOFFMANN-LA ROCHE LTD
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches & approvals
16.1.12.3.2 Deals
16.1.13 QUANTERIX CORPORATION
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Product launches & approvals
16.1.13.3.2 Deals
16.2 OTHER PLAYERS
16.2.1 BIO-TECHNE CORPORATION
16.2.2 SEEGENE INC.
16.2.3 MESO SCALE DIAGNOSTICS LLC
16.2.4 RANDOX LABORATORIES LTD.
16.2.5 STANDARD BIOTOOLS INC.
16.2.6 HOLOGIC, INC.
16.2.7 ABBOTT LABORATORIES
16.2.8 SIEMENS HEALTHINEERS AG
16.2.9 ENZO BIOCHEM INC.
16.2.10 SHIMADZU CORPORATION
16.2.11 PROMEGA CORPORATION
16.2.12 BOSTER BIOLOGICAL TECHNOLOGY
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY RESEARCH
17.1.1.1 Key data from secondary sources
17.1.2 PRIMARY DATA
17.1.2.1 Primary sources
17.1.2.2 Key data from primary sources
17.1.2.3 Key industry insights
17.2 MARKET SIZE ESTIMATION
17.2.1 BOTTOM-UP APPROACH
17.2.1.1 Approach 1: Company revenue estimation approach
17.2.1.2 Approach 2: Presentations of companies and primary interviews
17.2.1.3 Growth forecast
17.2.2 TOP-DOWN APPROACH
17.3 MARKET BREAKDOWN AND DATA TRIANGULATION
17.4 MARKET SHARE ANALYSIS
17.5 RESEARCH ASSUMPTIONS
17.5.1 PARAMETRIC ASSUMPTIONS
17.5.2 GROWTH RATE ASSUMPTIONS
17.6 RESEARCH LIMITATIONS
17.7 RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV (ALL AGES): 2010, 2023, AND 2024 (MILLION PEOPLE)
TABLE 2 ESTIMATED NUMBER OF NEW CANCER CASES IN BOTH SEXES: AGE 0-85+, 2022–2045
TABLE 3 TOTAL TB INCIDENCE, 2024
TABLE 4 IMPACT OF PORTER’S FIVE FORCES ON MULTIPLEX ASSAY MARKET
TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 7 EUROPE: MACROECONOMIC INDICATORS
TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 11 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026 (USD)
TABLE 12 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 13 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 14 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 15 MULTIPLEX ASSAY MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 17 KEY PATENTS IN MULTIPLEX ASSAY MARKET, 2022–2026
TABLE 18 KEY COMPANIES IMPLEMENTING AI IN MULTIPLEX ASSAY MARKET
TABLE 19 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
TABLE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES
TABLE 27 MULTIPLEX ASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 28 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 29 MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 EUROPE: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 GLOBAL: NUMBER OF MULTIPLEX ANALYZERS INSTALLED, 2024–2031 (UNITS)
TABLE 35 MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 EUROPE: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 EUROPE: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 46 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 47 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 EUROPE: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 63 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA
TABLE 68 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 69 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 EUROPE: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 EUROPE: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 95 MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 EUROPE: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 106 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 EUROPE: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 111 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 EUROPE: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2024–2031 (USD MILLION)
TABLE 116 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 EUROPE: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 126 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 128 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 EUROPE: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 EUROPE: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 144 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 EUROPE: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 ESTIMATED NUMBER OF CANCER CASES IN BOTH SEXES (AGE 0-85+), BY REGION, 2022 VS. 2030
TABLE 154 MULTIPLEX ASSAY MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 EUROPE: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 160 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 EUROPE: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 165 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 EUROPE: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 170 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 EUROPE: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 175 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 EUROPE: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 185 MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 191 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 EUROPE: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 196 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 EUROPE: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 201 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 EUROPE: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 206 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 MULTIPLEX ASSAY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 211 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
TABLE 212 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 213 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 215 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 219 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 220 NORTH AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221 NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 223 US: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 224 US: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225 US: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 US: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227 US: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 228 US: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 229 US: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230 US: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231 US: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 232 CANADA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 233 CANADA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 234 CANADA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 235 CANADA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 CANADA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 237 CANADA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 238 CANADA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239 CANADA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 240 CANADA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV (ALL AGES): 2010, 2023, AND 2024 (MILLION PEOPLE)
TABLE 2 ESTIMATED NUMBER OF NEW CANCER CASES IN BOTH SEXES: AGE 0-85+, 2022–2045
TABLE 3 TOTAL TB INCIDENCE, 2024
TABLE 4 IMPACT OF PORTER’S FIVE FORCES ON MULTIPLEX ASSAY MARKET
TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 7 EUROPE: MACROECONOMIC INDICATORS
TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 11 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026 (USD)
TABLE 12 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 13 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 14 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 15 MULTIPLEX ASSAY MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 17 KEY PATENTS IN MULTIPLEX ASSAY MARKET, 2022–2026
TABLE 18 KEY COMPANIES IMPLEMENTING AI IN MULTIPLEX ASSAY MARKET
TABLE 19 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
TABLE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES
TABLE 27 MULTIPLEX ASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 28 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 29 MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 EUROPE: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 GLOBAL: NUMBER OF MULTIPLEX ANALYZERS INSTALLED, 2024–2031 (UNITS)
TABLE 35 MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 36 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 EUROPE: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 EUROPE: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 46 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 47 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 EUROPE: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 63 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA
TABLE 68 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 69 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 EUROPE: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 EUROPE: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 95 MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 EUROPE: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 106 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 EUROPE: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 111 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 EUROPE: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2024–2031 (USD MILLION)
TABLE 116 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 EUROPE: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 126 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 128 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 EUROPE: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 EUROPE: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 144 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 EUROPE: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 ESTIMATED NUMBER OF CANCER CASES IN BOTH SEXES (AGE 0-85+), BY REGION, 2022 VS. 2030
TABLE 154 MULTIPLEX ASSAY MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 EUROPE: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 160 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 EUROPE: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 165 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 EUROPE: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 170 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 EUROPE: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 175 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 EUROPE: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 185 MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 191 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 EUROPE: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 196 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 EUROPE: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 201 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 EUROPE: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 206 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 MULTIPLEX ASSAY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 211 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
TABLE 212 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 213 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 215 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 219 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 220 NORTH AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221 NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 223 US: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 224 US: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225 US: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 US: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227 US: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 228 US: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 229 US: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230 US: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231 US: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 232 CANADA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 233 CANADA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 234 CANADA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 235 CANADA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 CANADA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 237 CANADA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 238 CANADA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239 CANADA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 240 CANADA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 MULTIPLEX ASSAY MARKET SEGMENTATION
FIGURE 2 MARKET HIGHLIGHTS AND KEY INSIGHTS
FIGURE 3 MULTIPLEX ASSAY MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MULTIPLEX ASSAY MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN MULTIPLEX ASSAY MARKET, 2026-2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 8 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 10 PROTEIN MULTIPLEX ASSAYS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 11 MULTIPLEX REAL-TIME PCR SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 12 RESEARCH & DEVELOPMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 15 MULTIPLEX ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 16 MULTIPLEX ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 17 MULTIPLEX ASSAY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 18 MULTIPLEX ASSAY MARKET: VALUE CHAIN ANALYSIS
FIGURE 19 MULTIPLEX ASSAY MARKET: ECOSYSTEM ANALYSIS
FIGURE 20 MULTIPLEX ASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 21 NUMBER OF DEALS AND FUNDING ACTIVITIES IN MULTIPLEX ASSAY MARKET
FIGURE 22 APPLIED AND GRANTED PATENTS, 2016–2025
FIGURE 23 MARKET POTENTIAL OF AI IN MULTIPLEX ASSAY MARKET
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
FIGURE 26 NORTH AMERICA: MULTIPLEX ASSAY MARKET SNAPSHOT
FIGURE 27 ASIA PACIFIC: MULTIPLEX ASSAY MARKET SNAPSHOT
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025 (USD MILLION)
FIGURE 29 MULTIPLEX ASSAY MARKET SHARE ANALYSIS, 2025
FIGURE 30 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 31 MULTIPLEX ASSAY MARKET: COMPANY FOOTPRINT
FIGURE 32 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 35 MULTIPLEX ASSAY MARKET: BRAND/PRODUCT COMPARISON FOR MULTIPLEX INSTRUMENTS
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
FIGURE 40 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025)
FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2025)
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 48 QUANTERIX CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 49 RESEARCH DESIGN
FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 52 MULTIPLEX ASSAY MARKET: REVENUE SHARE ANALYSIS
FIGURE 53 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 54 TOP-DOWN APPROACH
FIGURE 55 DATA TRIANGULATION METHODOLOGY
FIGURE 1 MULTIPLEX ASSAY MARKET SEGMENTATION
FIGURE 2 MARKET HIGHLIGHTS AND KEY INSIGHTS
FIGURE 3 MULTIPLEX ASSAY MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MULTIPLEX ASSAY MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN MULTIPLEX ASSAY MARKET, 2026-2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 8 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 10 PROTEIN MULTIPLEX ASSAYS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 11 MULTIPLEX REAL-TIME PCR SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 12 RESEARCH & DEVELOPMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 15 MULTIPLEX ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 16 MULTIPLEX ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 17 MULTIPLEX ASSAY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 18 MULTIPLEX ASSAY MARKET: VALUE CHAIN ANALYSIS
FIGURE 19 MULTIPLEX ASSAY MARKET: ECOSYSTEM ANALYSIS
FIGURE 20 MULTIPLEX ASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 21 NUMBER OF DEALS AND FUNDING ACTIVITIES IN MULTIPLEX ASSAY MARKET
FIGURE 22 APPLIED AND GRANTED PATENTS, 2016–2025
FIGURE 23 MARKET POTENTIAL OF AI IN MULTIPLEX ASSAY MARKET
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
FIGURE 26 NORTH AMERICA: MULTIPLEX ASSAY MARKET SNAPSHOT
FIGURE 27 ASIA PACIFIC: MULTIPLEX ASSAY MARKET SNAPSHOT
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025 (USD MILLION)
FIGURE 29 MULTIPLEX ASSAY MARKET SHARE ANALYSIS, 2025
FIGURE 30 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 31 MULTIPLEX ASSAY MARKET: COMPANY FOOTPRINT
FIGURE 32 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 35 MULTIPLEX ASSAY MARKET: BRAND/PRODUCT COMPARISON FOR MULTIPLEX INSTRUMENTS
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
FIGURE 40 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025)
FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2025)
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 48 QUANTERIX CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 49 RESEARCH DESIGN
FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 52 MULTIPLEX ASSAY MARKET: REVENUE SHARE ANALYSIS
FIGURE 53 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 54 TOP-DOWN APPROACH
FIGURE 55 DATA TRIANGULATION METHODOLOGY
